相关临床试验
14
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
42.9%
尚未招募
2
14.3%
招募中
4
28.6%
Unknown
2
14.3%
暂无批准数据
- The BioE3 Policy, approved in August 2024, has catalyzed over 270 funded projects across six thematic sectors including precision biotherapeutics, bio-based chemicals, and climate-resilient agriculture. - Seventeen biofoundry and biomanufacturing hub facilities have received funding, while 15 Bio-AI Hubs have been recommended to accelerate AI-driven biological design and translational research. - A BioE3-Strain Resource Centre has been established in Pune to provide indigenous microbial strains with freedom-to-operate, supporting the Make-in-India initiative and reducing reliance on imported technologies. - The GenomeIndia project has sequenced over 10,000 Indian genomes and identified nearly 180 million genetic variants, creating a foundation for AI/ML-driven precision medicine applications.
- India has announced the world's first clinical study to scientifically evaluate Ayurveda as an adjunct to standard Anti-Tuberculosis Treatment, marking a historic convergence of traditional medicine and modern biotechnology. - The landmark study will enroll 1,250 newly diagnosed TB patients across eight premier institutions, focusing on nutritional recovery, disease progression, quality of life improvements, and safety of integrative therapy. - India accounts for approximately 25% of the global TB burden but has achieved a 21% decline in incidence since 2015, with TB cases reduced to 187 per 100,000 population in 2024. - The collaborative initiative between the Department of Biotechnology and Ministry of Ayush will deploy advanced scientific tools including DEXA scans, MRI, immune profiling, and single-cell RNA sequencing to evaluate outcomes.
• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.
